BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
Low-grade ovarian serous carcinomas are believed to arise via an adenoma-serous borderline tumor-serous carcinoma sequence. In this study, we found that advanced-stage, low-grade ovarian serous carcinomas both with and without adjacent serous borderline tumor shared similar regions of loss of heterozygosity. We then analyzed 91 ovarian tumor samples for mutations in TP53, BRAF, and KRAS. TP53 mutations were not detected in any serous borderline tumors (n = 30) or low-grade serous carcinomas (n = 43) but were found in 73% of high-grade serous carcinomas (n = 18). BRAF (n = 9) or KRAS (n = 5) mutation was detected in 47% of serous borderline tumors, but among the low-grade serous carcinomas (39 stage III, 2 stage II, and 2 stage I), only one (2%) had a BRAF mutation and eight (19%) had a KRAS mutation. The low frequency of BRAF mutations in advanced-stage, low-grade serous carcinomas, which contrasts with previous findings, suggests that aggressive, low-grade serous carcinomas are more likely derived from serous borderline tumors without BRAF mutation. In addition, advanced-stage, low-grade carcinoma patients with BRAF or KRAS mutation have a better apparent clinical outcome. However, further investigation is needed.
Wong
Kwong-Kwok
KK
Departments of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. kkwong@mdanderson.org
Tsang
Yvonne T M
YT
Deavers
Michael T
MT
Mok
Samuel C
SC
Zu
Zhifei
Z
Sun
Charlotte
C
Malpica
Anais
A
Wolf
Judith K
JK
Lu
Karen H
KH
Gershenson
David M
DM
D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D018284:Cystadenocarcinoma, Serous / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D005260:Female; D020869:Gene Expression Profiling; D015894:Genome, Human; D006801:Humans; D009154:Mutation / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D010053:Ovary / Q000378:metabolism; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D015996:Survival Rate
D014408:Biomarkers, Tumor; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
Oncogene. 2005 Feb 3;24(6):1053-65
15558012
Am J Surg Pathol. 2005 Feb;29(2):218-24
15644779
Am J Surg Pathol. 1999 Apr;23(4):397-409
10199469
Obstet Gynecol. 2002 Jan;99(1):3-10
11777502
Nucleic Acids Res. 2004 May 17;32(9):e69
15148342
Am J Surg Pathol. 2002 Sep;26(9):1129-41
12218569
Am J Surg Pathol. 2006 Nov;30(11):1367-71
17063075
Dis Markers. 2007;23(5-6):377-87
18057521
Gynecol Oncol. 2006 Dec;103(3):883-7
16806438
Cancer Res. 2005 Jan 1;65(1):76-84
15665281
Gynecol Oncol. 2009 Jul;114(1):48-52
19361839
Am J Surg Pathol. 2005 Jun;29(6):707-23
15897738
Am J Surg Pathol. 1996 Nov;20(11):1319-30
8898836
Mol Cancer. 2009 Jul 30;8:53
19642975
Am J Surg Pathol. 2008 Nov;32(11):1667-74
18769340
Cancer. 1998 Mar 15;82(6):1096-103
9506355
PLoS Comput Biol. 2006 May;2(5):e41
16699594
Am J Surg Pathol. 2004 Apr;28(4):496-504
15087669
J Pathol. 2004 Mar;202(3):336-40
14991899
Cancer. 1998 Nov 15;83(10):2157-63
9827720
Genomics. 2002 Nov;80(5):465-72
12408963
Cancer Res. 2009 May 1;69(9):4036-42
19383911
Cancer Genet Cytogenet. 2006 Oct 1;170(1):1-8
16965948
Obstet Gynecol. 2006 Aug;108(2):361-8
16880307
Annu Rev Pathol. 2009;4:287-313
18842102
Am J Pathol. 2002 Apr;160(4):1223-8
11943707
Clin Cancer Res. 2005 Oct 15;11(20):7273-9
16243797
Cell Death Differ. 2010 Mar;17(3):452-8
19960022
Cancer Res. 2005 Nov 15;65(22):10602-12
16288054
Cancer Res. 2006 Dec 1;66(23):11172-8
17145861
Cancer Cell. 2009 Apr 7;15(4):294-303
19345328
Cancer Res. 2003 Aug 1;63(15):4299-304
12907594
Scand J Clin Lab Invest. 2009;69(4):452-9
19551557
Mod Pathol. 2005 Feb;18 Suppl 2:S19-32
15761464
Adv Anat Pathol. 2009 Sep;16(5):267-82
19700937
Int J Gynecol Pathol. 2003 Jan;22(1):37-41
12496696
J Natl Cancer Inst. 2003 Mar 19;95(6):484-6
12644542
Gynecol Oncol. 2007 Jun;105(3):625-9
17320156
Cell. 2008 Feb 8;132(3):363-74
18267069
Gynecol Oncol. 2008 Mar;108(3):510-4
18155273
Mol Carcinog. 2003 Feb;36(2):53-9
12557260
Bioinformatics. 2003 Dec 12;19(18):2397-403
14668223
Cancer Res. 2004 May 1;64(9):3060-71
15126342